Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nevro Corp. NVRO
$27.17
+$0.06 (0.22%)
На 18:00, 12 мая 2023
+153.96%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
984614828.00000000
-
week52high
53.34
-
week52low
26.40
-
Revenue
406365000
-
P/E TTM
420
-
Beta
0.86678200
-
EPS
0.07000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Overweight | Overweight | 04 авг 2022 г. |
| Piper Sandler | Neutral | Neutral | 04 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 07 июн 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 26 мая 2022 г. |
| Jefferies | Underperform | 12 окт 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 окт 2022 г. |
| Piper Sandler | Neutral | Neutral | 03 ноя 2022 г. |
| JP Morgan | Neutral | Neutral | 03 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 11 янв 2023 г. |
| Piper Sandler | Underweight | Neutral | 06 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 06 янв 2023 г. |
| Canaccord Genuity | Buy | Hold | 20 дек 2022 г. |
| Citigroup | Neutral | Buy | 17 янв 2023 г. |
| Piper Sandler | Underweight | Underweight | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| DEMANE MICHAEL F | A | 20001 | 662 | 30 дек 2022 г. |
| Fischer Frank M | A | 46817 | 422 | 30 дек 2022 г. |
| Kosaraju Sridhar | A | 8038 | 397 | 30 дек 2022 г. |
| WEATHERMAN ELIZABETH H | A | 44377 | 500 | 30 дек 2022 г. |
| Carter Richard B. | D | 13614 | 228 | 11 ноя 2022 г. |
| Carter Richard B. | D | 13842 | 719 | 01 ноя 2022 г. |
| Rashid Kashif | D | 61917 | 2134 | 01 ноя 2022 г. |
| Rashid Kashif | A | 64051 | 10710 | 04 окт 2022 г. |
| Kosaraju Sridhar | A | 7641 | 337 | 30 сент 2022 г. |
| DEMANE MICHAEL F | A | 19339 | 563 | 30 сент 2022 г. |
Новостная лента
Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued
Seeking Alpha
09 мая 2023 г. в 22:13
Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts could bring significant FCF growth and stock price appreciation.
Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
27 апр 2023 г. в 12:10
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript
Seeking Alpha
26 апр 2023 г. в 21:34
Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
26 апр 2023 г. в 18:59
Nevro (NVRO) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.98 per share a year ago.
How Much Upside is Left in Nevro (NVRO)? Wall Street Analysts Think 53.7%
Zacks Investment Research
25 апр 2023 г. в 11:28
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.